Incyte Announces Executive Leadership Appointments

Key Terms

cdk2 medical

Cyclin-dependent kinase 2 (CDK2) is a protein that helps control the timing of cell division, acting like a traffic light that tells cells when to enter different stages of growth and replication. Investors watch CDK2 because drugs that block or modify its activity can slow uncontrolled cell growth in cancers; changes in research, trials, or regulatory signals around CDK2-targeting therapies can affect the value and prospects of biotech companies.

krasg12d medical

KRAS G12D is a specific change in a cancer-linked gene that acts like a stuck switch, driving uncontrolled cell growth in some tumors. It matters to investors because this mutation defines a clear patient subgroup for targeted drugs and diagnostic tests, shaping clinical trial design, regulatory milestones, and potential market size—similar to how a recognizable car model creates demand for specialized parts and repairs.

late-stage development technical

Late-stage development is the final period when a product—often a drug, medical device, or other regulated offering—is tested, refined, scaled up for manufacturing, and prepared for regulatory approval and market launch. For investors this stage matters because it sharply reduces uncertainty: successful late-stage work is like finishing construction on a house and moving in—it signals the product is close to generating sales, while failures or delays can still wipe out expected value.

global medical affairs medical

A global medical affairs team is the scientific and clinical arm of a healthcare company that connects research, doctors, regulators and patients to ensure a drug or device is used safely and effectively around the world. Think of it as the company’s scientific customer support and translator—providing real-world data, medical education, safety monitoring and expert relationships that can influence regulatory approval, market acceptance and long‑term sales risk.

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans.

Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRAS^G12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive.

Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing late‑stage development programs across Hematology, Oncology and Immunology as well as Global Medical Affairs, a critical capability for data generation and reinforcing the Company’s scientific leadership throughout the healthcare community. A highly respected leader at Incyte for more than a decade, Dr. Stein’s scientific judgment, development expertise and patient-centric approach have been instrumental to the Company’s success.

Mohamed Issa, Pharm.D. has been appointed Executive Vice President and Head of U.S. Commercial. In this role, Mr. Issa will continue to oversee the U.S. Oncology business while assuming expanded responsibility for U.S. Immunology. These business units are being integrated into a single U.S. commercial organization to support strategic alignment and execution for new product launches, operational effectiveness and standardization of best practices. Mr. Issa is an experienced executive with a proven track record in new product launch planning and operations across both Oncology and Immunology, and his execution-oriented approach will be critical to sustain commercial performance at Incyte.

“These appointments reflect the significant contributions Pablo, Steven and Mohamed have made to Incyte and the value they continue to bring to the company,” said Bill Meury, Chief Executive Officer, Incyte. “Additionally, we are confident that integrating our U.S. commercial teams into one organization will drive effective launch execution and position Incyte for long-term success.”

As part of the transition, Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period.

For more background on Incyte’s Leadership Team, please visit https://incyte.com/our-company/our-leadership.

About Incyte^®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including any discussion of the strength of Incyte’s enterprise leadership and Incyte’s potential for future growth and long-term success.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, as detailed in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report on form 10-K for the year ended December 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260325544544/en/

Media
media@incyte.com

Investors
ir@incyte.com

Source: Incyte